AEON Biopharma Files 8-K for Reg FD and Financials

Ticker: AEON · Form: 8-K · Filed: Oct 7, 2024 · CIK: 1837607

Sentiment: neutral

Topics: regulatory-filing, financials

TL;DR

AEON Biopharma dropped an 8-K on Oct 7 for Reg FD and financials.

AI Summary

AEON Biopharma, Inc. filed an 8-K on October 7, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Priveterra Acquisition Corp., is incorporated in Delaware and has its principal executive offices in Irvine, CA.

Why It Matters

This filing provides important updates and disclosures for investors regarding AEON Biopharma's regulatory compliance and financial status.

Risk Assessment

Risk Level: low — This is a routine filing for regulatory and financial disclosures, not indicating any immediate operational or financial distress.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for AEON Biopharma, Inc.?

The primary purpose of this 8-K filing is to report on Regulation FD Disclosure and Financial Statements and Exhibits.

When was this 8-K filing submitted?

This 8-K filing was submitted on October 7, 2024.

What was AEON Biopharma, Inc. formerly known as?

AEON Biopharma, Inc. was formerly known as Priveterra Acquisition Corp.

In which state is AEON Biopharma, Inc. incorporated?

AEON Biopharma, Inc. is incorporated in Delaware.

What is the address of AEON Biopharma, Inc.'s principal executive offices?

The address of AEON Biopharma, Inc.'s principal executive offices is 5 Park Plaza, Suite 1750, Irvine, CA 92614.

Filing Stats: 541 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2024-10-07 17:01:10

Key Financial Figures

Filing Documents

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On October 7, 2024, AEON Biopharma, Inc. (the "Company" or "AEON") made available in the investor relations section of its website a new corporate presentation (the "Corporate Presentation"), a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this "Report"). Information from the Corporate Presentation may also be used by the management of the Company in future meetings regarding the Company. For important information about forward-looking statements in the Corporate Presentation, see the slide titled "Forward-Looking Statements" in Exhibit 99.1 attached hereto. The information furnished in this Item 7.01 of this Report (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference in such a filing.

01. Financial Statement and Exhibits

Item 9.01. Financial Statement and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Corporate Presentation of AEON Biopharma, Inc., dated October 2024 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AEON Biopharma, Inc. Date: October 7, 2024 By: /s/ Marc Forth Marc Forth Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing